(Q41095343)

English

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

scientific article published on 17 July 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 September 2017

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial (English)

1 reference

Europe PubMed Central

26 September 2017

anti-retroviral agent

0 references

6

object named as

Joseph J Eron

1 reference

Europe PubMed Central

26 September 2017

author name string

David A Margolis

1

1 reference

Europe PubMed Central

26 September 2017

Cynthia C Brinson

2

1 reference

Europe PubMed Central

26 September 2017

Graham H R Smith

3

1 reference

Europe PubMed Central

26 September 2017

Jerome de Vente

4

1 reference

Europe PubMed Central

26 September 2017

Debbie P Hagins

5

1 reference

Europe PubMed Central

26 September 2017

Sandy K Griffith

7

1 reference

Europe PubMed Central

26 September 2017

Marty H St Clair

8

1 reference

Europe PubMed Central

26 September 2017

Marita C Stevens

9

1 reference

Europe PubMed Central

26 September 2017

Peter E Williams

10

1 reference

Europe PubMed Central

26 September 2017

Susan L Ford

11

1 reference

Europe PubMed Central

26 September 2017

Britt S Stancil

12

1 reference

Europe PubMed Central

26 September 2017

Melinda M Bomar

13

1 reference

Europe PubMed Central

26 September 2017

Krischan J Hudson

14

1 reference

Europe PubMed Central

26 September 2017

Kimberly Y Smith

15

1 reference

Europe PubMed Central

26 September 2017

William R Spreen

16

1 reference

Europe PubMed Central

26 September 2017

LAI116482 Study Team

17

1 reference

Europe PubMed Central

26 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

17 July 2015

1 reference

Europe PubMed Central

26 September 2017

Lancet Infectious Diseases

1 reference

Europe PubMed Central

26 September 2017

15

1 reference

Europe PubMed Central

26 September 2017

10

1 reference

Europe PubMed Central

26 September 2017

1145-1155

1 reference

Europe PubMed Central

26 September 2017

Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900152-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900152-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900152-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900152-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Quad's in it for antiretroviral therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900152-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900152-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900152-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900152-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900152-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900152-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900152-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900152-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900152-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-acting injectable antiretrovirals for HIV treatment and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900152-8

7 January 2021

based on heuristic

inferred from DOI database lookup

GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900152-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900152-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900152-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900152-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900152-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1473-3099(15)00152-8

1 reference

Europe PubMed Central

26 September 2017

1 reference

Europe PubMed Central

26 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41095343&oldid=2093453638"